- Ahvenanmaa
- Etelä-Karjala
- Etelä-Pohjanmaa
- Etelä-Savo
- Itä-Uusimaa
- Kainuu
- Kanta-Häme
- Keski-Pohjanmaa
- Keski-Suomi
- Kymenlaakso
- Lappi
- Päijät-Häme
- Pirkanmaa
- Pohjanmaa
- Pohjois-Karjala
- Pohjois-Pohjanmaa
- Pohjois-Savo
- Satakunta
- Uusimaa
- Varsinais-Suomi
Our partners
News from Rova
Fortgeschrittenster Kandidat des 2008 gegründeten Unternehmens ist das Antikörper-Wirkstoff-Konjugat "Rova-T" (Rovalpituzumab + Pyrrolobenzodiazepin), das an Krebszellen bindet, die das Protein Delta-like 3 exprimieren. Rova-T wird derzeit in frühen ...
Fortgeschrittenster Kandidat des 2008 gegründeten Unternehmens ist das Antikörper-Wirkstoff-Konjugat "Rova-T" (Rovalpituzumab + Pyrrolobenzodiazepin), das an Krebszellen bindet, die das Protein Delta-like 3 exprimieren. Rova-T wird derzeit in frühen ...
AbbVie (NYSE:ABBV) said it will acquire Stemcentrx and its lead late-stage asset rovalpituzumab tesirine (Rova-T) currently in registrational trials for small cell lung cancer (SCLC). The transaction is valued at about $5.8 billion, with additional ...
"We initially assume peak sales of c$1.5bn for Rova-T in 2nd/ 3rd line SCLC based on c50% penetration of an estimated eligible c30,000 DLL3 +ve patient 2nd/ 3rd line population in the US/EU5 and c$100,000 revenue per patient," the firm wrote in a note.
Stemcentrx's most valuable asset happens to be its investigational cancer drug, Rova-T, which is currently in mid-stage studies, being evaluated as a treatment for small-cell lung cancer. This is a particularly difficult-to-treat cancer that accounts ...
On Thursday, it doubled down on a high-risk, high-reward M&A strategy by paying $5.8 billion for the closely held drug developer Stemcentrx and its late-stage lead drug for small-cell lung cancer, Rova-T. If the deal works out, then AbbVie will be a ...
Photos from Rova
Zip Code from Rova
91510
Rova
Hotels
